active brain body prevent effects possibility consequences mice lacking bace1 birth developmental effects not apply enzyme activity lowered adults results helped propel testing blown clinical trials making verubecestat bace1 inhibitor reach phase iii trials molecule kind combine amyloid]-lowering potency positive safety profile allows treat patients time needed determine clinical benefits cognition kennedy says trials testing long term outcomes patients ongoing involves roughly 2,000 patients mild moderate alzheimer 18 months second 1,500 participants early signs alzheimer indicated amyloid plaques revealed positron emission tomography brain scans years big issue long term safety drugs vassar says people drugs rest lives trials years happens